RxSight, Inc. (RXST) Earnings Call Analysis

NASDAQ · Healthcare · Medical Devices

Earnings Reports

• RxSight (RXST) Q2 2026: Core Sales Drop 20% as Competitive Trialing Hits Premium IOL Demand
  July 07, 2026
• RxSight (RXST) Q1 2026: LAL Mix Hits 88% of Revenue as Utilization Stabilizes
  May 07, 2026
• RxSight (RXST) Q4 2025: LAL Mix Hits 86% as LDD Sales Drop 64%, Shifting Margin Profile
  February 26, 2026
• RxSight (RXST) Q3 2025: LAL Mix Jumps to 85%, Resetting Margin Baseline
  November 06, 2025
• RxSight (RXST) Q2 2025: LDD Sales Drop 49% as Utilization Refocuses Growth Strategy
  August 08, 2025
• RxSight (RXST) Q1 2025: LAL Revenue Rises 37% as Macro and Competitive Friction Delays Recovery
  July 04, 2025
• RxSight (RXST) Q4 2024: LAL Procedure Volume Surges 61% as Adjustable IOL Adoption Expands
  February 25, 2025
• RxSight (RXST) Q3 2024: LDD Installed Base Jumps 51% as Premium IOL Adoption Deepens
  November 09, 2024

Browse all companies